| Copy number variation at 1q21. 1 associated with neuroblastoma SJ Diskin, C Hou, JT Glessner, EF Attiyeh, M Laudenslager, K Bosse, ... Nature 459 (7249), 987-991, 2009 | 446 | 2009 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 411 | 2020 |
| Common variations in BARD1 influence susceptibility to high-risk neuroblastoma M Capasso, M Devoto, C Hou, S Asgharzadeh, JT Glessner, EF Attiyeh, ... Nature genetics 41 (6), 718-723, 2009 | 344 | 2009 |
| Integrative genomics identifies LMO1 as a neuroblastoma oncogene K Wang, SJ Diskin, H Zhang, EF Attiyeh, C Winter, C Hou, RW Schnepp, ... Nature 469 (7329), 216-220, 2011 | 317 | 2011 |
| RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma KA Cole, J Huggins, M Laquaglia, CE Hulderman, MR Russell, K Bosse, ... Proceedings of the National Academy of Sciences 108 (8), 3336-3341, 2011 | 285 | 2011 |
| Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations KR Bosse, JM Maris Cancer 122 (1), 20-33, 2016 | 237 | 2016 |
| Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma KR Bosse, P Raman, Z Zhu, M Lane, D Martinez, S Heitzeneder, KS Rathi, ... Cancer cell 32 (3), 295-309. e12, 2017 | 180 | 2017 |
| Rare Variants in TP53 and Susceptibility to Neuroblastoma SJ Diskin, M Capasso, M Diamond, DA Oldridge, K Conkrite, KR Bosse, ... Journal of the National Cancer Institute 106 (4), dju047, 2014 | 125 | 2014 |
| Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity KR Bosse, SJ Diskin, KA Cole, AC Wood, RW Schnepp, G Norris, ... Cancer research 72 (8), 2068-2078, 2012 | 119 | 2012 |
| GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity S Heitzeneder, KR Bosse, Z Zhu, D Zhelev, RG Majzner, MT Radosevich, ... Cancer Cell 40 (1), 53-69. e9, 2022 | 102 | 2022 |
| RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs M Yarmarkovich, QF Marshall, JM Warrington, R Premaratne, A Farrel, ... Nature 599 (7885), 477-484, 2021 | 97 | 2021 |
| Genetic susceptibility to neuroblastoma: current knowledge and future directions LE Ritenour, MP Randall, KR Bosse, SJ Diskin Cell and tissue research 372, 287-307, 2018 | 75 | 2018 |
| Epigenetic state determines inflammatory sensing in neuroblastoma AJ Wolpaw, LD Grossmann, JL Dessau, MM Dong, BJ Aaron, PA Brafford, ... Proceedings of the National Academy of Sciences 119 (6), e2102358119, 2022 | 35 | 2022 |
| LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase D Chen, J Cox, J Annam, M Weingart, G Essien, KS Rathi, JL Rokita, ... Neoplasia 22 (6), 231-241, 2020 | 27 | 2020 |
| Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes Y Feng, Y Wang, Z Zhu, W Li, RT Sussman, M Randall, KR Bosse, ... MAbs 8 (4), 799-810, 2016 | 26 | 2016 |
| Suspected posaconazole toxicity in a pediatric oncology patient J Martino, BT Fisher, KR Bosse, R Bagatell Pediatric blood & cancer 62 (9), 1682, 2015 | 25 | 2015 |
| Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma KR Bosse, AM Giudice, MV Lane, B McIntyre, PM Schürch, ... Cancer discovery 12 (12), 2800-2819, 2022 | 24 | 2022 |
| Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors JB Foster, C Griffin, JL Rokita, A Stern, C Brimley, K Rathi, MV Lane, ... Journal for Immunotherapy of Cancer 10 (9), 2022 | 23 | 2022 |
| A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope S Raman, SN Buongervino, MV Lane, DV Zhelev, Z Zhu, H Cui, ... Cell Reports Medicine 2 (7), 2021 | 20 | 2021 |
| Targeting of intracellular oncoproteins with peptide-centric CARs M Yarmarkovich, QF Marshall, JM Warrington, R Premaratne, A Farrel, ... Nature 623 (7988), 820-827, 2023 | 18 | 2023 |
